In this online CME self-learning program: Opioid use disorder (OUD) affects millions of individuals globally and is best defined by the DSM-5 as a condition due to tolerance, manifestation of physical dependence, and loss of control, which in turn leads to health hazards. The prevalence of OUD and the resultant impact on people is staggering, an estimated 130 people die from opioid overdoses every day. Moreover, the prevalence of OUD is increasing rapidly in concurrence with the widespread availability of opioids, with an estimated 60 prescriptions per 100 patients.
Professional societies, non-governmental organizations, and governmental agencies have all recommended a comprehensive public health approach to identifying and managing OUD, which will require the involvement of HCPs across specialties and regions. Implementing a comprehensive multidisciplinary cascade of care for patients with OUD will also necessitate that HCPs embrace new resources to deliver innovative and accessible health care. These resources may include novel prescription digital therapeutics, telemedicine, and engagement of non-physician HCPs who can provide support, counseling, and, in some cases, prescribing.
Healthcare professionals specializing in: Addiction, pain management, primary care, family medicine, psychiatry; physician assistants, nurse practitioners, nurses, and pharmacists who practice in pain management or substance abuse; and any other health professionals who encounter OUD in the clinical setting.
This program is supported by educational grants from Indivior and The Modami Foundation.
Learners may participate in this activity free of charge.
Release Date: March 20, 2021 -- Expiration Date: March 20, 2023
Faculty: Michael Levine, MD
Faculty introduction, disclosures
Epidemiology of OUD
Treatment of OUD
Summary, conclusions, and best practice recap
By the end of the session the participant will be able to:
ACCME Activity #201718496
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Michael Levine, MD, Department of Emergency Medicine, University of California, Los Angeles, has no relevant conflicts of interest to disclose.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant conflicts of interest to disclose.
Commercial Support Disclosure: This program is supported by educational grants from Indivior and The Modami Foundation.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Opioid dependence and opioid use disorder: Best practices, barriers in care, and the role of long-acting injectable medication
Updates in alcohol use disorder (AUD) pharmacotherapy and barriers to optimal care
Bipolar and mood disorder: Therapeutic updates and best practices
Addressing barriers to optimal care in schizophrenia with pharmacotherapy